
Kite to Buy Interius BioTherapeutics for $350 Million, Advancing In Vivo CAR T Strategy
SANTA MONICA, CA & PHILADELPHIA, PA — Kite, a Gilead company (Nasdaq: GILD), has agreed to acquire Interius BioTherapeutics for $350 million in cash, a move aimed at bringing in …
Kite to Buy Interius BioTherapeutics for $350 Million, Advancing In Vivo CAR T Strategy Read More